2026 Antenatal Bartter syndrome strategy: epidemiology, NKCC2 biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Primary distal renal tubular acidosis strategy: epidemiology, AE1 biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Congenital anomalies of kidney and urinary tract strategy: epidemiology, RET biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Immunotactoid glomerulopathy strategy: epidemiology, CD20 biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Congenital nephrotic syndrome strategy: epidemiology, NPHS1 biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Fibrillary glomerulonephritis strategy: epidemiology, DNAJB9 biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Dense deposit disease strategy: epidemiology, Complement C3 biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Steroid-resistant nephrotic syndrome strategy: epidemiology, APOL1 biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Cardiac allograft vasculopathy strategy: epidemiology, mTOR biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Inappropriate sinus tachycardia strategy: epidemiology, HCN4 biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Postural orthostatic tachycardia syndrome strategy: epidemiology, HCN4 biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Takotsubo cardiomyopathy strategy: epidemiology, Beta-1 adrenergic receptor biology, clinical competition, recent deals, unmet need and market attractiveness.